Tegavivint for Large B-Cell Lymphoma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines a new drug, tegavivint, to determine its safety and effectiveness for individuals with certain types of large B-cell lymphoma that have recurred or resisted other treatments. Tegavivint blocks enzymes essential for cancer cell growth, potentially helping to control the disease. This study suits those who have undergone at least two previous lymphoma treatments and are ineligible for or have declined certain advanced therapies. Participants will receive tegavivint through an IV and undergo several scans and blood tests to monitor its effects. As a Phase 1 trial, this research aims to understand how tegavivint works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I need to stop my current medications to join the trial?
The trial information does not specify whether you need to stop taking your current medications. However, if you are on HIV medications or other drugs that interact with tegavivint, you may not be eligible to participate.
Is there any evidence suggesting that tegavivint is likely to be safe for humans?
Research has shown that tegavivint is safe and tolerable in patients with other tumors, such as desmoid tumors. Patients generally handled the treatment well, with most side effects being mild. In studies involving patients with advanced liver cancer, certain doses of tegavivint also appeared safe, with mostly mild side effects reported.
As this is a Phase 1 trial, the main goal is to assess the safety of tegavivint in people with relapsed or refractory large B-cell lymphoma. Earlier studies in different conditions suggest it might be well-tolerated, but this trial will help confirm its safety for large B-cell lymphoma.12345Why do researchers think this study treatment might be promising?
Tegavivint is unique because it targets the TBL1 protein, which plays a critical role in the growth of large B-cell lymphoma. Unlike standard treatments like chemotherapy, which broadly attack fast-growing cells and can lead to significant side effects, Tegavivint offers a more targeted approach, potentially reducing collateral damage to healthy cells. Researchers are excited about its ability to specifically disrupt cancer cell signaling pathways, which might offer a more effective and less toxic treatment option for patients.
What evidence suggests that tegavivint might be an effective treatment for large B-cell lymphoma?
Research has shown that tegavivint, the investigational treatment in this trial, might stop tumors from growing by blocking signals cancer cells need. Early lab studies found that tegavivint can shrink tumors with a protein called beta-catenin, which aids cell growth. This is crucial because, in certain large B-cell lymphomas, especially those that recur or resist treatment, standard therapies often fail. By targeting the beta-catenin pathway, tegavivint might offer a new approach to managing these challenging cancers. These early results are promising, but ongoing studies must confirm its effectiveness.12467
Who Is on the Research Team?
Lapo Alinari, MD, PhD
Principal Investigator
Ohio State University Comprehensive Cancer Center
Are You a Good Fit for This Trial?
Adults with relapsed or refractory large B-cell lymphoma who have tried at least two treatments and can't or won't get stem cell transplant or CAR T-cell therapy. They must have measurable disease, adequate organ function, agree to use contraception, and not be pregnant. Excluded are those with certain infections, recent major surgery, other active cancers (with exceptions), uncontrolled illnesses, known allergies to similar drugs, HIV on specific treatments, active CNS lymphoma.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive tegavivint intravenously (IV) and undergo CT and/or PET scans and blood sample collection throughout the trial
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Tegavivint
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lapo Alinari
Lead Sponsor